CMV retinitis in the era of HAART

Ocular Immunology and Inflammation

Volumn 7, Issue 3-4, 1999, Pages 231-235

  Cassoux, N ^a   Bodaghi, B ^a   Katlama, C ^a   Lehoang, P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

AIDS related opportunistic infections; CMV retinitis; Fluorescein angiography; HAART; HIV therapy; Immune recovery; Protease inhibitors; Uveitis; Vitritis

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; HUMAN; INCIDENCE; LYMPHOCYTE COUNT; PROGNOSIS; RETINITIS; VIRUS LOAD;

EID: 0033372145     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.1076/ocii.7.3.231.4008     Document Type: Conference Paper

References (25)

1. 1 Holland GN, Tufail A, Jordan MC. Cytomegalovirus diseases. In: Pepose J, Holland G, Wilhelmus K, editors. Ocular Infection and Immunity. St Louis: Mosby, 1996; 1088-1128.
2. 2 Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology 1994;101:1250-1261.
3. 3 Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. J Infect Dis 1997;176:50-58.
4. 4 Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Arch Intern Med 1995;155:65-74.
5. 5 Thorne JE, Jabs DA, Vitale S, Miller T, Dunn JP, Semba RD. Catheter complications in AIDS patients treated for cytomegalovirus retinitis. AIDS 1998;12:2321-2327.
6. 6 CDC. Trends in AIDS incidence, deaths, and prevalence United States 1996. MMWR 1997;46:165-173.
7. 7 WHO. European center for the epidemiological monitoring of AIDS. HIV/AIDS Surveillance in Europe 1997;55:44/50.
8. 8 Walsh JC, Jones CD, Barnes EA, Gazzard BG, Mitchell SM. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 1998;12:613-618.
9. 9 Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
10. 10 Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
11. 11 Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998;126: 817-822.
12. 12 Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-1187.
13. 13 Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997;124:199-205.
14. 14 Van den Horn GJ, Meenken C, Danner SA, Reiss P, De Smet MD. Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. Br J Ophthalmol 1998;82: 988-990.
15. 15 Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998; 105: 1259-1264.
16. 16 Jouan MSM, Tubiana R, Cassoux N, Olivier C, Carcelain G, Fillet AM, Senechal B, Nciri M, Tural C, Mussini C, Gerard M, Bricaire F, Chêne G, Katlama C and the RESTIMOP Study Group. Presented at the Sixth Conference on Retrovirus and Opportunistic Infections, January 31, 1999, Chicago, IL, USA.
17. 17 Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443-1445.
18. 18 Karavellas MP, Lowder CY, Macdonald C, Avila CP Jr., Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998;116:169-175.
19. 19 Magone MT, Nussenblatt RB, Whitcup SM. Elevation of laser flare photometry in patients with cytomegalovirus retinitis and AIDS. Am J Ophthalmol 1997;124:190-198.
20. 20 Althaus C, Best J, Hintzmann A, Schimkat M, Hudde T, Cepin A, et al. Endothelial precipitates and laser flare photometry in patients with acquired immunodeficiency syndrome: a screening test for cytomegalovirus retinitis? Ger J Ophthalmol 1996;5: 443-448.
21. 21 Karavellas MP, Plummer DJ, Macdonald JC, Torriani FJ, Shufelt CL, Azen SP, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179:697-700.
22. 22 Cassoux N, Lumbroso L, Bodaghi B, Zazoun L, Katlama C, LeHoang P. Cystoid macular edema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy. Br J Ophthalmol 1999;83:47-49.
23. 23 Herbort CP, Chave JP. Cicatrization of cytomegalovirus retinitis following introduction of highly active antiretroviral therapy: uveitis as a possible indicator of good ocular prognosis. Graefe's Arch Clin Exp Ophthalmol 1998;236:795-797.
24. 24 Karavellas MP, Lowder CY, Macdonald C, Avila Jr CP, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1999;116:169-175.
25. 25 Canzano JC, Reed JB, Morse LS. Vitreomacular traction syndrome following highly active antiretroviral therapy in AIDS patients with cytomegalovirus retinitis. Retina 1998;18:443-447.